BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T220320
CREATED:20230202T105002Z
LAST-MODIFIED:20230324T110700Z
UID:36448-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Cell Engager Summit
DESCRIPTION:The 5th Annual Cell Engager Summit is back in Boston\, MA this year – the only industry-led meeting bringing together 100+ pharma and biotech leaders will assemble for a 3-day agenda including 4 unique pre-conference workshops to delve into the biggest challenges cell engager therapeutics face. Breaking into the solid tumor\, preventing CRS and maximizing the quality of insights we gain from preclinical modeling. \nFor unmissable opportunities\, including: \n\nGain first-hand knowledge of the difficulties of developing kinase inhibitors to improve selectivity\, cross the blood-brain barrier\, and combat resistance\nUtilize cutting-edge platforms and technologies to maximise target validation and precisely predict off-target impacts to save time and costs\nEstablish long-lasting relationships by speaking with top pharma and biotech firms that are working on kinase inhibitor medicines and looking for the best-in-class solutions directly\n\nJoin your colleagues from the likes of Apexigen\, Regeneron Pharmaceuticals\, Genentech\, Roche\, Amgen\, Boehringer Ingelheim and many more at the most comprehensive cell engager event\, leaving no stone unturned\, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it. \nDownload the full event guide for your sneak peek.
URL:https://www.pharmajournalist.com/event/5th-cell-engager-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T220320
CREATED:20230202T110212Z
LAST-MODIFIED:20230202T110212Z
UID:36461-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Neuroimmunology Drug Development Summit
DESCRIPTION:With increasing prioritization for neuroscience discovery\, huge biopharma is investing in expanding its departments\, focusing on glial biology\, neuroinflammatory biomarkers\, and optimizing various approaches to target the likes of LRKK2\, TREM2\, and more. Therefore\, there is a great amount of novel and promising research to be discussed in 2023. \nUniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications\, including AD\, PD\, ALS\, and MS\, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery\, preclinical\, translational\, and clinical experts from the likes of Genentech\, Muna Therapeutics\, Biogen\, Janssen\, Bristol Myers Squibb\, Sanofi\, Takeda\, and Roche. \nWith new speakers from the hottest biopharma in neuroimmunology delivering\, a comprehensive program of pioneering and cutting-edge content\, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy\, creation\, and implementation of research\, biomarker\, and clinical hypothesis testing in neuroimmunology. \nTo know more visit: https://ter.li/w642sd
URL:https://www.pharmajournalist.com/event/5th-neuroimmunology-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T220320
CREATED:20230207T094958Z
LAST-MODIFIED:20230207T094958Z
UID:36542-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Gene Therapy Durability Summit
DESCRIPTION:Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit\, join us to: \n\nLeverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV\nBetter understand what can be extrapolated and how to gain confidence in the data collected\nBuild study designs with durability in mind and explore how well preclinical models have predicted clinical durability to date\n\nHear from the likes of Pfizer\, Selecta Biosciences\, Spark Therapeutics\, Rocket Pharmaceuticals\, ASC Therapeutics and more across a preconference workshop day\, expert presentations\, interactive panel discussions\, dedicated Q&A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nWhen you attend you will: \n\nUnderstand the regulatory requirements to determine robust durability\nExplore the challenges short term immunogenicity has on durability\nNavigate how to overcome long term immunogenicity concerns on durability\nOptimize vectors constructs to maximize gene therapy durability\nDiscover how to better predict the translational success of durability when progressing from preclinical to clinical trials\n\nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/oeczu3
URL:https://www.pharmajournalist.com/event/gene-therapy-durability-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T220320
CREATED:20230227T130914Z
LAST-MODIFIED:20230227T130914Z
UID:36686-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:2nd ADC Analytical Development Summit 2023
DESCRIPTION:The 2nd ADC Analytical Development Summit (April 25-27\, 2023 | Boston\, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC\, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions\, to enhance understanding of your drug and to exert control over your process. \nSee the complete 2023 event guide here. \nWith many new ADCs under development\, the analytical challenges are only increasing as the existing hurdles keep changing\, with the regulatory guidance still being limited. This is a unique touch point for drug developers to discuss the core analytical challenges the industry is facing including drug linkers\, drug substances\, drug formulation\, and drug products. \nYou and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including: \n\nYuan Gao\, Head of Analytical Development\, ADC Therapeutics \nJessica Webb\, Scientist\, Analytical Sciences\, AstraZeneca\nGuifeng Jiang\, Head of Analytical Development Pharmaceutical Operation\, Bolt Biotherapeutics\nThomas Gardinier\, Head of Materials Analysis\, Elucida Oncology\nSimon Letarte\, Director\, Gilead\nAdrienne Wildt\, Senior Director of Analytical Development\, ImmunoGen\nShuwen Sun\, Principal Scientist\, Merck & Co\nVimal Patel\, Vice President\, Head of CMC & Supply Chain\, Orum Therapeutics\nJulie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nSarah Owen\, Senior Scientist Potency Assays\, Seagen\nMelvin Flores\, Director Quality Control Analytical & Microbiology\, Sutro Biopharma\nMay Zhu\, Director of Analytical Development- External Interface Management\, Takeda\n\nJoin them here. \nWith 100+ attendees\, 4+ hours of dedicated networking\, and 3 days of exciting new content\, including a pre-conference focus day on comparability studies\, this is a conversation you won’t want to miss to hopefully\, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval
URL:https://www.pharmajournalist.com/event/2nd-adc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230426
DTEND;VALUE=DATE:20230428
DTSTAMP:20260515T220320
CREATED:20230126T113838Z
LAST-MODIFIED:20230310T095341Z
UID:36359-1682467200-1682639999@www.pharmajournalist.com
SUMMARY:6th Annual Pharmaceutical Microbiology USA Conference
DESCRIPTION:6th Annual Pharmaceutical Microbiology USA Conference\nApril 26 – 27\, 2023 \nBoston\, MA\, USA \nhttp://www.pharma-microbiology-usa.com/PharmaJournalistWL \nSponsored by: LONZA \nChaired by: Donald Singer\, USP General Chapter Committee Microbiology Chair\, US Pharmacopeia  \nContamination Control and Microbial Methods Explored to Assure Product Quality and Prevention \nMicrobiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals\, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches. \nEnsuring the sterility of the finished product continues to be one of the most critical aspects of drug development\, however an array of factors is also sustaining new growth and transformation in this field. The regulatory landscape is changing\, firstly with the preparation of Annex I\, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination\, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms\, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement. \nOn top of this\, the developing integration of automation and robotics into the manufacturing pipeline\, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs\, are all highlighting the necessity of the field in Pharma. \nThis industry is ever expanding\, join our leading experts at the 6th Annual Pharmaceutical Microbiology East Coast Conference in Boston\, USA to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with the  industry professionals\, discuss revisions in regulatory and guidance documents\, and gain a deeper insights. \nEvent Hashtag: #MicrobiologyUSA  \nKey Conference Highlights: \n\nReview implementation guidance and validation for efficient microbial testing programs\nUncover how to implement effective contamination control for manufacturing and the impact throughout pharmaceutical microbiology\nLearn how to control mold contamination and apply risk-based tools to tackle recovery\nDelve into the role the microbiologist plays in bioburden assessments and holistic closure integrity testing for new drug modalities\nUnderstand innovative techniques to control contamination as it relates to cell therapy products\, combination\, and traditional microbiological drug products\n\nView the full agenda: http://www.pharma-microbiology-usa.com/PharmaJournalistWL
URL:https://www.pharmajournalist.com/event/6th-annual-pharmaceutical-microbiology-usa-conference/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230502
DTEND;VALUE=DATE:20230505
DTSTAMP:20260515T220320
CREATED:20230111T113431Z
LAST-MODIFIED:20230111T113431Z
UID:36220-1682985600-1683244799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy Analytical Development Europe Summit 2023
DESCRIPTION:Uniting leading CMC\, Regulatory\, QC\, Analytical and Process Development experts\, the 4th Annual Gene Analytical Development Europe Summit is the industry’s definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development. \nHear from the likes of AstraZeneca\, MHRA\, Gyroscope\, REGENXBIO\, Biogen\, Spark Therapeutics\, and more across three days and two tracks of in-depth case studies\, interactive panel discussions\, dedicated Q&A time\, and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nDon’t miss the opportunity to network with 80+ analytical experts to overcome your analytical challenges encountered in every stage of the gene therapy development life cycle. \nTo know more visit: https://ter.li/q8u3rf
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-analytical-development-europe-summit-2023/
LOCATION:The Tower Hotel\, St. Katharine's Way\, London\, E1W 1LD\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230509
DTEND;VALUE=DATE:20230512
DTSTAMP:20260515T220320
CREATED:20230227T131842Z
LAST-MODIFIED:20230227T131842Z
UID:36691-1683590400-1683849599@www.pharmajournalist.com
SUMMARY:4th STING & TLR Targeting Therapies Summit
DESCRIPTION:Facilitating key conversations needed to drive forward the development of safe and effective innate stimulating immunotherapies\, the 4th STING & TLR Targeting Therapies Summit will take place\, for the first time ever in person\, in Boston on May 9-11\, 2023. \nView the official program here. \nExplore innate agonists from discovery to translation with the leaders in the space and gain insight into clinical updates\, unpack what went wrong with some failures like ADU-S100 and address critical challenges including driving down toxicity\, preclinical model selection and choosing appropriate delivery mechanisms. \nHere are some exciting highlights you cannot miss including: \n\nReviewing the clinical landscape in the past year\, key updates in innate agonists that have moved through the clinic\, and identifying the root of failed trials through integral discussions led by Beacon Targeted Therapies\, Tempest Therapeutics\, and #Indaptus Therapeutics\nAssessing the best innate agonist delivery approaches\, from data on antibody-conjugated STING agonists with Takeda Oncologyand ImmuneSensor to unpacking 7&8 Biopharma’s IV delivery to extracellular vesicle approaches with Codiak Bio \nRevisiting cancer vaccines and navigating their development with post-COVID vaccine considerations; with Elicio Therapeuticsand UT Southwestern Medicine\, exploring the use of STING / TLR adjuvants to deliver on this promising therapeutic\nVenturing beyond oncology to learn from drug developers utilizing STING & TLR agonists to treat infectious diseases and adding these potent innate activators to our arsenal to be better equipped for the next pandemic\n\nView the complete agenda and speaker line-up. \nBeing the only meeting dedicated to driving forward the development of innate immune agonists\, we encourage you to take this exciting opportunity to unite and leverage the industry’s cumulative knowledge and experience to have meaningful conversations that will translate STING & TLR agonists into effective and reliable treatment options.
URL:https://www.pharmajournalist.com/event/4th-sting-tlr-targeting-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260515T220320
CREATED:20230323T113857Z
LAST-MODIFIED:20230323T113857Z
UID:36881-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:Highly Potent Active Pharmaceutical Ingredients Conference 2023
DESCRIPTION:The Global High Potency API/HPAPI Market is projected to reach 37 billion USD by 2027\, growing at an ever-increasing CAGR of 8.43%. The expanding production of high potency APIs\, along with the increase in associated toxicities\, are driving requirements for more effective containment solutions and much-needed guidelines to ensure worker safety. \nOur 2023 conference brings insights from leading pharmaceutical companies on how to improve hazard identification\, integrate advanced containment controls and mitigate the risk of manufacturing HPAPI. Featuring leading speakers including directors\, engineers\, and experts in validation requirements this conference provides an extensive look at how you can futureproof your pharmaceutical manufacturing facilities. \nThis two-day conference offers you peer-to-peer networking with industry experts including heads and directors of EHS\, Occupational Hygiene\, Quality Assurance and more. Expand your community and explore the latest developments in the industry at this two-day event\, including key regulatory updates\, and leading case studies from leading pharmaceutical and biotechnology companies. \nBenefits of Attending the HPAPI Conference: \n\nLEARN how to ensure advanced therapeutic manufacturing is safe for workers and patients\nINCREASE the effectiveness of your engineering containment controls by improving harmony between the worker engineer and toxicologist to ensures cost-effective design choices\nUNCOVER the best practises & opportunities for pharmaceutical companies to work alongside CMOs to effectively and efficiently scale-up HPAPI manufacturing\nREVIEW case studies on the implementation of risk-based hazard identification strategies from leading pharmaceutical companies including AstraZeneca\, CSL Behring and Merck\n\nDISCOVER future trends in containment and control technologies to future-proof your HPAPI manufacturing plant to maximsie operator safety \nTo know more visit: www.highlypotentapi.com/PharmaJournalistEL
URL:https://www.pharmajournalist.com/event/highly-potent-active-pharmaceutical-ingredients-conference-2023/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230510
DTEND;VALUE=DATE:20230512
DTSTAMP:20260515T220320
CREATED:20230323T114213Z
LAST-MODIFIED:20230323T114213Z
UID:36887-1683676800-1683849599@www.pharmajournalist.com
SUMMARY:5th Annual Injectable Drug Delivery Conference
DESCRIPTION:Exploring Injectable Drug Formulations and Device Development \nSponsors: Victrex \nExhibitors: PHC Group  \nAs Part of Europe’s leading Injectable conference series\, the 5th annual Injectable Drug Delivery conference will assess innovations in drug product formulation and biologics\, new technologies in device design\, along with the latest regulatory considerations for optimal drug delivery. \n \nWith increasing demand for vaccines\, insulin\, and many other modern medicines administered via the injectable route\, there is significant growth projected in the biologics market\, particularly the injectable drug delivery and prefilled syringe market which is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. It is due to this rising demand and increased growth that the industry must come together to discuss and critically evaluate the next generation of injectable drug delivery. \nAt this year’s event we will highlight the most recent innovations within the industry\, with regard to injectable device design and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. In silico modelling will be addressed as we continue to see a move towards AI utilisation\, alongside key CMC concerns and usability of injectable devices in digital health. The conference will also highlight the significance of sustainability within the industry\, whilst providing regulatory insight on the changes that have occurred and are forecast in the coming years. \nBenefits of attending: \n\nExplore the latest trends within the Injectable drug delivery field\, with new insights into in-silico modelling\nExpand on current knowledge of device design\, with special considerations for primary and secondary packaging\nExamine injectable drug formulation strategies\, including novel formulation methodologies\nLearn how to advance the injectable drug delivery landscape through a review of current regulatory compliance\nRealise how Chemical Manufacturing and Control can further expand the industry through digitalisation strategies\n\nTo know more visit: http://www.injectable-drug-delivery.com/PharmaJournalist-EI
URL:https://www.pharmajournalist.com/event/5th-annual-injectable-drug-delivery-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230516
DTEND;VALUE=DATE:20230518
DTSTAMP:20260515T220320
CREATED:20221209T121926Z
LAST-MODIFIED:20221209T122048Z
UID:36016-1684195200-1684367999@www.pharmajournalist.com
SUMMARY:Reuters Events: Digital Health 2023
DESCRIPTION:It’s a painful moment for healthcare. We face rampant burn out\, squeezed operating margins\, unhappy patients\, massive cost pressures and more competition than ever as disruptors continue to flood the market with convenient\, accessible care options. \nIt’s high time we collaborate around Digital Health. We must listen\, take note and work to implement the changes that our care staff and consumers demand to force the disruptive change required. Fixing our broken healthcare system demands a collective effort to connect disparate data\, streamline clinical workflows\, slash costs\, and zero in on consumer orientated\, digitally enabled care delivery. \nReuters Events: Digital Health USA 2023 (May 16-17\, San Diego) hosts 300+ digital leaders over two intensive days of collaborating\, networking\, and learning opportunities tailored to digital\, strategy\, innovation\, transformation\, information\, information security\, data science backgrounds\, to help accelerate the transformation that our consumers desire and our care teams deserve. \nTo know more visit: https://bit.ly/3F7cD60
URL:https://www.pharmajournalist.com/event/reuters-events-digital-health-2023/
LOCATION:Mission Bay Resort\, 1775 E Mission Bay Dr.\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Natalie.Diaz-Martin@thomsonreuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230516
DTEND;VALUE=DATE:20230519
DTSTAMP:20260515T220320
CREATED:20230202T110613Z
LAST-MODIFIED:20230202T110719Z
UID:36466-1684195200-1684454399@www.pharmajournalist.com
SUMMARY:2nd ALS Drug Development Summit
DESCRIPTION:With 3 days of jam-packed content and 35+ world class speakers pioneering the next wave of ALS therapies\, the 2nd ALS Drug Development Summit is biopharma’s can’t-miss meeting for the acceleration of ALS drug development pipelines. \nJoin 100+ of your biopharma peers to uncover cutting-edge ALS biomarkers\, including neurofilament light chain\, to incorporate into clinical trials\, improve in vitro and in vivo ALS preclinical models to improve translation of safe and efficacious therapies and optimize clinical trial design and endpoints to maximise data collection in an evolving standard of care. \nBrowse the full Event Guide to discover:\n\n37+ expert ALS speakers across 3 jam-packed conference days\, spanning all stages of the drug development pipeline\n\n\nDoubled pre-conference workshop content\, with 4 deep-dive workshops facilitating interactive discussions on novel ALS target discovery\, preclinical strategy\, wearable technology\, and clinical trial design\n\n\nOpening conference discussion on recent and upcoming FDA approvals to learn key takeaways from interacting with regulatory bodies\n\n\nHear directly from patient advocates and individuals living with ALS to understand their perspective on ALS drug development and engagement in clinical research\n\n\nDedicated networking\, roundtable discussion and poster sessions to share your insights with other ALS leaders in the room\n\nTo know more visit: https://ter.li/21k4zy
URL:https://www.pharmajournalist.com/event/2nd-als-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230530
DTEND;VALUE=DATE:20230602
DTSTAMP:20260515T220320
CREATED:20230222T124243Z
LAST-MODIFIED:20230222T124243Z
UID:36641-1685404800-1685663999@www.pharmajournalist.com
SUMMARY:5th Treg Summit
DESCRIPTION:With investment into the Treg field at an all time high\, excitement is overflowing at the prospect of these remarkable cells being game-changers in the long-term treatment of autoimmunity\, inflammation and transplantation. As this enthusiasm coincides with multiple clinical readouts and several more therapies entering the clinic\, it remains vital for Treg trailblazers to come together to recognize therapy efficacy\, determine safety and translate the next-generation of therapies into the clinic. \nThe Treg Summit returns for the 5th year to unite this dedicated community of industry and academic experts\, and remains the go-to industry forum to advance both cell and non-cell based approaches to unlock the potential of Tregs to treat indications with huge unmet clinical need. \nWith 3 jam-packed days of content across CAR-\, TCR– and polyclonal Tregs as well as IL-2\, muteins and small molecules\, you won’t want to miss this unrivalled opportunity to collaborate with your peers in the Treg field to explore clinical advances\, discuss challenges and discover next-gen methods to take Treg therapies to the next level. \nWhy Attend Now? \n\nOver $2 billion has been thrown into the Treg space in the past 8 months alone\, reflecting the potential of these therapies\n2022 saw the first-ever dosing of a human with a CAR-Treg cell therapy paving the way for the rest of the engineered Treg field\nVital clinical updates determine the safety and efficacy of Treg modulating therapies\n\nSecure your place today – https://ter.li/jddnbx
URL:https://www.pharmajournalist.com/event/5th-treg-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260515T220320
CREATED:20230208T093703Z
LAST-MODIFIED:20230208T093703Z
UID:36555-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:2nd Cell Therapy Potency Assay Summit
DESCRIPTION:The 2nd Cell Therapy Potency Assay will gather 100+ experts working to rationally design better potency assays to smooth the path to regulatory approval and minimize hold times with scientifically rigorous and informative potency measurements. \nWhether you are submitting your first IND or gearing up towards BLA submission\, this critical meeting of minds is your premier opportunity to join the likes of bluebird bio\, Arsenal Bio\, Takeda\, Merck\, Sana Biotechnology and more\, to gain critical updates on regulatory interactions and unpick how industry peers are approaching potency assay development. \nLeave this meeting equipped with industry insights to understand what potency assays are showing\, develop practical\, compatible\, reproducible assays; and better characterize your cell therapy products for targeted\, untargeted\, allogeneic and autologous platforms in oncology and non-oncology indications. \nTo know more visit: https://ter.li/zc871s
URL:https://www.pharmajournalist.com/event/2nd-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230531
DTEND;VALUE=DATE:20230603
DTSTAMP:20260515T220320
CREATED:20230307T092630Z
LAST-MODIFIED:20230307T092630Z
UID:36769-1685491200-1685750399@www.pharmajournalist.com
SUMMARY:5th Age-Related Disease Therapeutics Summit
DESCRIPTION:Whether it’s in cardiovascular disease\, Alzheimer’s or osteoarthritis\, therapeutic innovations to target the mechanisms of aging are making significant headway to clinical trials. With increased investments and recognition\, along with the escalation of the burden of age-related disease\, research and development to meet this unmet medical need has never been more important. \nThe 5th Age-Related Disease Therapeutics Summit is the only industry-focused meeting dedicated to uniting 100+ biopharma drug developers\, pioneering academics\, and prominent investors striving to develop effective\, novel drugs that promote healthy aging and overcome major translational and regulatory obstacles. \nJam-packed with the most cutting-edge insights and opportunities to reunite with and hear from your peers on the next steps forward in developing the safest and most efficacious drug to promote a healthier and enhanced quality of life. \nTo know more visit: https://ter.li/sl5og6
URL:https://www.pharmajournalist.com/event/5th-age-related-disease-therapeutics-summit/
LOCATION:Marines Memorial Club and Hotel\, 609 Sutter St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260515T220320
CREATED:20230202T110957Z
LAST-MODIFIED:20230202T110957Z
UID:36469-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotides for CNS Summit
DESCRIPTION:With approvals in siRNA technology\, more ASOs hurtling towards human trials in neurology\, and exciting headlines in Alzheimer’s and ALS\, the draw of CNS targets for oligonucleotides has never been greater. Massive investments and growing pipelines in pharma and biotech alike are working to make these life-changing therapies a reality for previously undruggable targets. \nJoin 100+ experts and dedicated scientists at the 3rd Oligonucleotides for CNS\, the definitive industry forum bringing together leaders to problem-solve\, explore invention\, and inspire the creation of next-generation oligonucleotide drugs for neurological disorders. Gather with specialists from Biogen\, Ionis\, Genentech\, Eli Lilly\, Servier\, and Stoke\, spanning disciplines of biology\, chemistry\, toxicology\, and clinical innovation. \nTackle genomic target validation\, backbone chemistry\, effective intracellular delivery\, and potency\, increased stability for reduced dosing\, novel cerebral organoids\, CNS device delivery\, and CSF oligo distribution to uncover the best approaches for each phase in your pipeline. Take away invaluable lessons that will translate directly into optimizing your oligonucleotide pipeline for the CNS. \nTo know more visit: https://ter.li/i5y7zn
URL:https://www.pharmajournalist.com/event/3rd-oligonucleotides-for-cns-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230606
DTEND;VALUE=DATE:20230609
DTSTAMP:20260515T220320
CREATED:20230207T095425Z
LAST-MODIFIED:20230207T095425Z
UID:36545-1686009600-1686268799@www.pharmajournalist.com
SUMMARY:4th Annual Gene Therapy for Neurological Disorders Summit Europe
DESCRIPTION:Returning as the pinnacle event in the industry\, the 4th Annual Gene Therapy for Neurological Disorders Summit Europe (6-8 June 2023\, Amsterdam) enables you to bring your gene therapy to patients in Europe. This year’s content takes a greater focus on: \n\nInnovation in preclinical models and vector technology\nShowcasing novel approaches to improve delivery in a safe manner\nOptimizing administration route to reduce the patient\nUnderstanding what needs to be done to crack the European market\n\nDownload the agenda to find out more – https://ter.li/1mmd4t \nCovering both neurodevelopmental and neurodegenerative disorders\, join 80+ of your peers in Amsterdam this June. We’ll be welcoming those leading biopharma and academia\, working in preclinical\, clinical and market access to help get safer\, more efficacious gene therapies for neurological disorders to market in Europe. \nAs the gene therapy community gets a second wind and as the clinical promise in neurology begins to be realised\, now is the time to get your hands on the latest innovations in this field to bring safe\, efficacious and commercially successful products to market in Europe.  \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/azxig5
URL:https://www.pharmajournalist.com/event/4th-annual-gene-therapy-for-neurological-disorders-summit-europe/
LOCATION:Room Mate Aitana\, IJdok 6\, 1013 MM\, Amsterdam\, 1013 MM\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230612
DTEND;VALUE=DATE:20230614
DTSTAMP:20260515T220320
CREATED:20230323T114637Z
LAST-MODIFIED:20230323T114637Z
UID:36890-1686528000-1686700799@www.pharmajournalist.com
SUMMARY:6th Annual Pre-Filled Syringes West Coast Conference
DESCRIPTION:Assessing Device Development and Regulation for Advanced Innovation\nSponsors: Datwyler\, Haselmeier\, Mitsubishi Gas Chemical\, Nemera\, ZEON \nExhibitors: Credence MedSystems\, Kymanox\, Noble\, Owen Mumford Pharmaceutical Services\, SCHERDEL Medtec \nSAE Media Group’s 7th Annual Pre-Filled Syringes West Coast Conference will be back for 2023 in San Diego to bring together the device developers\, innovative biotech\, and big pharma. \nThis year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \nWith the injectable drug delivery industry rapidly advancing year-to-year\, administration using pre-filled syringes\, auto-injectors\, and pen-injectors are increasingly common. Innovations in device technology\, such as connected devices are leading the way in device design in addition to injectable delivery devices for novel and large volume drugs. With the need for self-administration growing\, there is an enhanced demand for on-body injectors and digitalised health as well as patient centricity. We are beginning to see environmental sustainability being incorporated into aspects of device lifecycle from design to manufacturing and the use of the device. This year’s conference looks to address these hot topics through case studies and industry insights. \nAs part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring delegates key insights to enhance their drug device portfolio\, but it will also give them the opportunity to network with key industry players.  \nBenefits of Attending: \n\nEngage with industry representatives about the latest technologies and advances within the injectable device market and directions to take to advance your device portfolio\nGain insight into new technologies for wearable injectors he delivery of novel and large volume drugs\nUnderstand the latest regulatory requirements and guidance to ensure your combination products are compliant such as meeting essential performance requirements\nDelve into aspects of primary packaging such as material components to consider during device design to ensure drug stability and safety\nExplore how digital technologies such as companion apps are being incorporated into drug delivery devices to improve user-centricity\n\nWho should attend: \nDirectors\, Heads of Departments and Managers for the following areas: \n\nDevice Development\nDevice Engineering\nCombination Product Development\nDrug Delivery Devices\nPrimary Packaging Development\nDigital Health\nLarge Volume Drug Delivery\nNovel Drug Product Formulation\nRegulatory Affairs\n\nEarly Bird Rates: \n\nEB1 – 28 Feb 2023 – US$400\nEB2 -31 March 2023 – US$200\nEB3 – 28 April 2023 – US$100\n\nAdditional Contact Info: \nT: +44 (0)20 7827 \nE: Hannah.Blake@saemediagroup.com \nW: http://www.prefilled-syringes-westcoast.com/PharmaJournalist-El
URL:https://www.pharmajournalist.com/event/6th-annual-pre-filled-syringes-west-coast-conference/
LOCATION:San Diego\, CA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T220320
CREATED:20230228T084503Z
LAST-MODIFIED:20230228T084623Z
UID:36697-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd Annual Gene Therapy Patient Engagement
DESCRIPTION:As the global healthcare system accelerates its acceptance of gene therapies as one-time\, potentially curative\, treatment options for rare diseases\, the role of patient engagement in informing drug development strategy is evolving. \nAt this interface lies the 3rd Gene Therapy Patient Engagement Summit\, uniting patient advocacy and engagement experts from leading gene therapy and gene editing drug developers\, along with patient groups and patients themselves. Talks\, workshops\, and group discussions will shed a light on how to better integrate the patient voice into gene therapy programs at crucial stages of the drug development process. \nJoin us in Boston this summer to gain the actionable insights\, tools\, and strategies you need to better implement patient input into patient-centric gene therapy programs. \nTo know more visit: https://ter.li/rbofji
URL:https://www.pharmajournalist.com/event/3rd-annual-gene-therapy-patient-engagement/
LOCATION:Westin Boston Seaport\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T220320
CREATED:20230320T154738Z
LAST-MODIFIED:20230320T154738Z
UID:36873-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:Temperature Control and Logistics Summit
DESCRIPTION:Advance your end-to-end logistics strategy to deliver vital therapeutics at the RIGHT TIME\, RIGHT PLACE and the RIGHT TEMPERATURE \nJoin us in Frankfurt in June 2023 in a brand-new venue at the heart of Europe\, as once again\, we return live and in-person for 3 days of interactive sessions\, collaborative roundtables as well as formal and informal networking to maximise the value of shared insights and open discussions. \nWe meet at a time of great challenge and opportunity. How can we mitigate risk and ensure quality whilst adopting the new technologies essential to future success? In what ways can we bolster the resilience of our supply chains without compromising operational agility? How can we build a supply chain and logistics network that is both effective and environmentally sustainability? \nOnly in partnering across the supply chain can we confront these challenges; and as a community that thrives on innovation and collaboration\, we’ve built a programme centred on the fundamental challenges of our time\, including how we: \n>> Drive Digital Transformation Throughout The Supply Chain To Achieve Full End-To-End Visibility\n>>Enhance Supply Chain & Logistics Network Design To Bolster Resilience\, Security & Efficiency\n>> Partner Across The Network To Meet The Demands of An Increasingly Complex Operating Environment\n>> Leverage New Packaging Innovation To Ensure Quality & Demonstrate Regulatory Compliance\n>> Build An Environmentally Sustainability Temperature Controlled Supply Chain \nTCL 2023 will provide a deep-dive into what these industry developments mean for Pharmaceutical Logistics\, Quality Assurance & Supply Chain practitioners and focus on delivering a mix of interactive sessions\, which will enable delegates to leverage the collective knowledge of their peers and brainstorm solutions to the challenges\, which the industry is facing. \nTCL doesn’t just stand for Temperature Control and Logistics\, now it also stands for Transformation\, Collaboration and Learning! >> Download the full agenda to view full speaker line-up\, discussion details\, sponsorship opportunities\, and more!
URL:https://www.pharmajournalist.com/event/temperature-control-and-logistics-summit/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="IQPC Limited":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230613
DTEND;VALUE=DATE:20230616
DTSTAMP:20260515T220320
CREATED:20230503T050638Z
LAST-MODIFIED:20230503T050638Z
UID:37123-1686614400-1686873599@www.pharmajournalist.com
SUMMARY:3rd ILD Summit
DESCRIPTION:Returning for the 3rd year\, the ILD Summit will lean into the industry’s key challenges\, explore pipeline opportunity development\, and look towards the future for ILD therapeutic development from idiopathic pulmonary fibrosis pipelines. From illuminating predictors of progression to define and identify the progressive fibrosis phenotypes for patient stratification to evolving clinical trial design with novel secondary and exploratory endpoints beyond FVC. This is a fantastic point in 2023 for the lung fibrosis community to come together to meet at the intersection of pulmonology and rheumatology to advance therapeutic development for ILDs. \nTo know more visit: https://ter.li/wc2uto
URL:https://www.pharmajournalist.com/event/3rd-ild-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T220320
CREATED:20230314T122048Z
LAST-MODIFIED:20230314T122048Z
UID:36825-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:Next Gen Inhalation Delivery Summit
DESCRIPTION:With exciting developments in pioneering inhaled drug products from Moderna\, Vertex\, ReCode Therapeutics\, and Pieris Pharmaceuticals\, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029\, achieving cell-specific delivery\, and optimized stability remain vital challenges. \nThis June\, the hotly anticipated Next Gen Inhalation Delivery Summit will debut\, where we will unite 80+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD\, asthma\, IPF\, lung cancer or infectious disease\, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery. \nBe part of the conversation in Boston this June\, where we unpick: \n\nOvercoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit\nAdvancing your inhalation formulation techniques for improved stability and longer shelf-lives\nEnsuring device-formulation compatibility with patient compliance and patient convenience\n\nWith key speakers from the likes of Janssen\, Avalyn Pharma\, and FDA\, exciting content\, and networking opportunities\, you cannot afford to miss out! \nTo know more visit: https://ter.li/hlg9tw
URL:https://www.pharmajournalist.com/event/next-gen-inhalation-delivery-summit/
LOCATION:The Bostonian\, 26 North St\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230620
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T220320
CREATED:20230330T101610Z
LAST-MODIFIED:20230330T102722Z
UID:36955-1687219200-1687478399@www.pharmajournalist.com
SUMMARY:2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Exciting results are expected this year\, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73\, CD39 and A2AR! \nTo ensure the community can capitalize on this\, the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit will be returning this June (20 – 22) in Boston\, MA – dedicated to bringing together 80+ industry experts to tackle the biggest problems the field continues to face in discovering translating and clinically developing CD73\, CD39\, A2A and A2B focused therapeutics. \nJoin this unmissable 3-day meeting to explore the biology of the receptors and enzymes opening doors to new therapeutic opportunities at the discovery stage\, utilize novel technologies and approaches through translation to clinical development to improve patient selection\, and discover new ways of finding mono and combo therapy approaches to increase potency and safety. \nTop Speakers includes: \n\nAlex Gaither\, Vice president from Exscientia AI – evaluating ways to improve preclinical engineering practices for adenosine mono & combo therapeutics candidates\nChangyun Hu\, CSO from Adept Therapeutics – deep diving into preclinical and clinical Adenosine receptor targeting and more\nJoanne Lager\, Chief Medical Officer from iTeos Therapeutics – looking beyond T Cell and assessing potential outcomes for the Adenosine field in the event of an approval or major failure\n\n& 15+ more expert speakers! \nDownload your copy of the newly released agenda to find everything that will help you translate and clinically develop your adenosine therapeutic: https://ter.li/hende5 \nInterested in speaking? Contact info@hansonwade.com \nInterested in sponsoring? Contact sponsor@hansonwade.com
URL:https://www.pharmajournalist.com/event/2nd-annual-adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230621
DTEND;VALUE=DATE:20230623
DTSTAMP:20260515T220320
CREATED:20230309T105108Z
LAST-MODIFIED:20230309T105108Z
UID:36775-1687305600-1687478399@www.pharmajournalist.com
SUMMARY:Antimicrobial Resistance Connect Europe
DESCRIPTION:This event will take place in London on 21-22 June 2023 in London\, focusing on the three biggest priorities enabling growth in the AMR field – Innovation\, Investment & Policy – AMR Connect enables you to foster connections with key stakeholders in anti-microbial research and build actionable next steps to combat the silent pandemic. \n \nAMR Connect provides your team with the opportunity to create actionable steps within an interdisciplinary environment\, creating a unified approach across sectors. The demand to innovate and advance the way we tackle resistance is paramount and commanding the attention of nations globally – book your place now and join us in tackling the silent pandemic. \nBenefits of attending \n\nWith AMR considered one of the top 10 public health threats globally\, uncover how different regions are developing effective policy guidelines and incentive schemes that work for their region – with sessions from ReAct Latin America\, Asia-Europe Foundation\, WHO and many more.\nApply for the Innovation Showcase\, showcasing your state-of-the-art research in drug development\, diagnostics or one health in front of our room of investors\, pharma and solution providers.\nStreamline your route from discovery to market through case studies from Arrepath and Madam Therapeutics on the utilisation of AI/ML to reduce drug development timescales.\nMeet your next partner and foster connections across stakeholders through future-focussed roundtables on the biggest challenges impacting the field – including regulation\, policy and the future of anti-infectives.\n\nTake advantage of the early bird discount ending on 24 March. Book now to SAVE up to £700.
URL:https://www.pharmajournalist.com/event/antimicrobial-resistance-connect-europe/
LOCATION:LONDON\,UK
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230627
DTEND;VALUE=DATE:20230630
DTSTAMP:20260515T220320
CREATED:20230207T095639Z
LAST-MODIFIED:20230207T095639Z
UID:36549-1687824000-1688083199@www.pharmajournalist.com
SUMMARY:3rd Annual Next Generation Gene Therapy Vectors Summit
DESCRIPTION:As the biggest industry-led meeting on novel vector development\, the 3rd Annual Next Generation Gene Therapy Vectors Summit (June 27-29\, 2023 | Boston\, MA) will bring together 100+ key opinion leaders to help solve the safety\, efficiency\, and scalability challenges of the next generation of vectors. \nIndustry heavyweights such as Novartis\, Spark Therapeutics\, Capsida Biotherapeutics\, and Dyno Therapeutics will deliver data-led seminars\, workshops\, and panels to aid in the progression of promising vector designs from discovery to clinical trials. \nDownload the brochure to see the full agenda – https://ter.li/b6qdwn \nUniting industry pioneers such as Dave Chu (Capsida Biotherapeutics)\, Sean Armour (Spark Therapeutics)\, Eric Kelsic (Dyno Therapeutics)\, Jing Liao (Alexion Pharmaceuticals)\, and others – this summit will be your ultimate roadmap to the future of the industry as it upgrades to the next generation of vectors. \nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/qlplw9
URL:https://www.pharmajournalist.com/event/3rd-annual-next-generation-gene-therapy-vectors-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230628
DTEND;VALUE=DATE:20230701
DTSTAMP:20260515T220320
CREATED:20230413T095125Z
LAST-MODIFIED:20230413T095125Z
UID:37050-1687910400-1688169599@www.pharmajournalist.com
SUMMARY:8th Microbiome Movement Drug Development Summit
DESCRIPTION:The 8th Microbiome Movement Drug Development Summit returns in 2023 as North America’s definitive microbiome drug development event – and it’s back bigger and better than ever! \nThe microbiome-based therapeutic market is rapidly evolving\, and it’s more important than ever to showcase the efficacy of microbial-based approaches beyond C. difficile. Discover how drug developers are advancing their understanding of the role of the microbiome in disease and harnessing functionally relevant microbes for live biotherapeutic approaches. \nJoin us\, as we provide in-depth insights into the interactions between the microbiome and metabolic pathways\, host-microbe relationships in novel preclinical models\, and the application of microbial-based biomarkers in clinical endpoints and diagnostic settings. Our sessions also cover the mechanistic rationale behind combination therapies\, new smart clinical trial data\, and GMP compliant manufacturing for stable products. \nWith more speakers\, content\, and networking than ever before\, this is set to be the best version of the event yet and you cannot afford to miss it! \nTo know more visit: https://microbiome-summit.com/
URL:https://www.pharmajournalist.com/event/8th-microbiome-movement-drug-development-summit/
LOCATION:Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260515T220320
CREATED:20230302T092937Z
LAST-MODIFIED:20230302T092937Z
UID:36706-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Digital Biomarkers & Clinical Measures in Neurology Summit
DESCRIPTION:CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective\, frequent\, sensitive\, and less invasive measures of movement\, speech\, and cognition. \nReturning to Boston\, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit is the only industry-specific meeting dedicated to developing translatable\, scalable\, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials. \nThis is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development. \nUniting Digital Health Biopharma with CNS Clinical Drug Developers to: \n\nAddress the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications\nDiscover Novel Innovations for Objective\, Sensitive\, & Non-Invasive Neurological Measures\nEnsure Confidence & Scalability with Emerging Digital Technologies\n\nTo know more visit: https://ter.li/nx0m2f
URL:https://www.pharmajournalist.com/event/2nd-digital-biomarkers-clinical-measures-in-neurology-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230711
DTEND;VALUE=DATE:20230714
DTSTAMP:20260515T220320
CREATED:20230405T231354Z
LAST-MODIFIED:20230405T231354Z
UID:37027-1689033600-1689292799@www.pharmajournalist.com
SUMMARY:2nd Annual Optimizing AAV Safety Summit 2023
DESCRIPTION:With more than 300 trials in preclinical and clinical development actively using AAV as their vector of choice\, the priority for any company working in this space is to ensure that each and every one of those therapies is the safest version it can be. \nIn this context\, the 2nd Annual Optimizing AAV Safety Summit is returning in 2023\, bringing together genetic therapy leaders across non-clinical development\, clinical development\, toxicology\, biodistribution\, and immunology who are all working to optimize the safety of their AAV-based drug products in their day-to-day. \nBy addressing key topics including how to extract the most relevant data from preclinical studies to better inform how humans will respond to an AAV-based therapy in the clinic\, analyzing potential integration risks of AAV serotypes\, and investigating regulatory approaches to safety packages for submission\, this meeting will inform how to streamline AAV safety processes to de-risk delays and shorten timelines to approval. \nJoin us in Boston to be part of the solution to bringing safer\, effective genetic therapies to patients and gain immediately implementable insights to sharpen your programs currently in preclinical and clinical development. \nTo know more visit: https://ter.li/6gzgy4
URL:https://www.pharmajournalist.com/event/2nd-annual-optimizing-aav-safety-summit-2023/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230712
DTEND;VALUE=DATE:20230714
DTSTAMP:20260515T220320
CREATED:20230404T110544Z
LAST-MODIFIED:20230404T110544Z
UID:37012-1689120000-1689292799@www.pharmajournalist.com
SUMMARY:Advanced Wound Care Summit US 2023
DESCRIPTION:The Advanced Wound Care Summit is wound care’s only industry-led forum \nIt’s a chance for senior executives to address shared challenges around innovative product development\, build meaningful partnerships\, and sharpen their R&D and commercial strategies. \nWhether an established wound care company\, an emerging startup\, an SME\, a regulator\, a payer\, or key opinion leader\, this event serves your strategic and commercial goals. \nTo take this chance to uncover how leading figures are leveraging novel clinical trial designs\, addressing reimbursement challenges surrounding skin substitute products\, progressing next generation diagnostic innovations\, and much more. \nTo know more visit: https://hubs.ly/Q01J-t480
URL:https://www.pharmajournalist.com/event/advanced-wound-care-summit-us-2023/
LOCATION:Boston\, Massachusetts
ORGANIZER;CN="Kisaco Research":MAILTO:Jodie.purser@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230718
DTEND;VALUE=DATE:20230721
DTSTAMP:20260515T220320
CREATED:20230414T110135Z
LAST-MODIFIED:20230414T110135Z
UID:37065-1689638400-1689897599@www.pharmajournalist.com
SUMMARY:3rd Tumor Myeloid-Directed Therapies Summit
DESCRIPTION:The 3rd Annual Tumor Myeloid-Directed Therapies Summit returns with over 75% new speakers to share insights across a range of myeloid targets\, including CD40\, CD39\, LILRB2\, CLEC-1 as well as CAR-M therapies. The one-stop shop continues to be your go-to forum to accelerate myeloid therapy progression by determining optimal combination strategy\, optimize translational studies\, discover novel targets\, and guarantee patient safety. Connect with this up-and-coming community to reinvent targeting and harness the untapped potential of the myeloid. \nCollaborate and learn from myeloid experts across industry and academia over 3 in-depth days of content\, as they address the key bottlenecks limiting the efficacy and safety of these exciting treatments\, including in vivo models\, biomarkers of response\, combination rationale\, and myeloid biology to accelerate myeloid directed therapies. \nTo know more visit: https://ter.li/tm1bzy
URL:https://www.pharmajournalist.com/event/3rd-tumor-myeloid-directed-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230725
DTEND;VALUE=DATE:20230728
DTSTAMP:20260515T220320
CREATED:20230405T225751Z
LAST-MODIFIED:20230405T225751Z
UID:37019-1690243200-1690502399@www.pharmajournalist.com
SUMMARY:ADC Toxicity Summit
DESCRIPTION:There is a vast number of ADCs that never make it to the clinic let alone to market\, and this is largely due to toxicological challenges providing a narrow therapeutic index. Understanding the causes of toxicity\, their translatability into the clinic\, as well as mitigation and dosing strategies to limit these toxicities will enable ADC developers to take more assets into the clinic while reducing the costs of failures. \nThe inaugural ADC Toxicity Summit is coming to Boston\, MA this July 25-27 as the first and only meeting dedicated to enabling drug developers to analyze mechanisms of action\, discuss shared challenges associated with translating in vivo toxicity data to the clinic\, and optimizing dosing to minimize the toxicity of your drug and improve tolerability to bring more ADCs with a wider therapeutic index to market. \nTake a look at our 3-day event guide for your in-depth roadmap to the ADC Toxicity Summit. \nUniting all key stakeholders invested in this conversation ranging from toxicologist and pathologists\, through to nonclinical\, translational\, and clinical experts\, this is your exclusive opportunity to harness never before gained insights to deliver a safer and more tolerable generation of ADCs to patients. \n3 reasons why you can’t miss out on joining include: \n\nSelect optimal preclinical models for determining ADC toxicity profiles to enable improved translatability and ultimately improve clinical trial outcomes with Seagen and AbbVie\nHear how companies with commercially approved ADCs mitigated toxicities in the clinic\, and optimized their dosage allowing expansion of their therapeutic windows with ImmunoGen and the Dana Farber Cancer Institute\nUncover ideal linker stability and drug-antibody ratios to design an ADC with a lower toxicity profile with Bristol Myers Squibb\, Iksuda and Merck & Co\n\nHarnessing case-study led presentations and interactive discussions to enable you to select optimal models for your GLP toxicity studies\, mitigate ADC related toxicities in the clinic and optimize linker-design for more controlled payload release\, this is your exclusive opportunity to harness new insights to minimize the toxicity of your drug.
URL:https://www.pharmajournalist.com/event/adc-toxicity-summit/
LOCATION:Hyatt Regency Boston Downtown\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR